LUCD Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.80%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $5,820.65

Lucid Diagnostics Insider Trading History Chart

Lucid Diagnostics Share Price & Price History

^$0.67

▼ -0.01 (-1.47%)

As of 04/25/2024 01:00 AM ET

Days: 30 | 90 | 365

The Gold Grab of the Century

From Colonial Metals | Ad

When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.

That's why we have released our Free Precious Metals Investment Guide.

Lucid Diagnostics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/25/2023	Stanley Lapidus	Director	Sell	200	$1.43	$286.00	131,339
9/20/2023	Stanley Lapidus	Director	Sell	3,817	$1.45	$5,534.65	131,639
9/20/2022	Stanley Lapidus	Director	Sell	33,864	$1.70	$57,568.80	135,456

The Gold Grab of the Century

From Colonial Metals | Ad

When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.

That's why we have released our Free Precious Metals Investment Guide.

SEC Filings (Institutional Ownership Changes) for Lucid Diagnostics (NASDAQ:LUCD)

74.01% of Lucid Diagnostics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Lucid Diagnostics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/14/2023	Luminus Management LLC	878,378	$1.22M	0.4%	+2.7%	2.024%
2/13/2023	Levin Capital Strategies L.P.	36,799	$50K	0.0%	N/A	0.094%
11/15/2022	Cantor Fitzgerald L. P.	264,653	$0.41M	0.0%	-20.7%	0.698%
11/14/2022	Luminus Management LLC	846,662	$1.30M	0.5%	-3.1%	2.232%
11/14/2022	Verition Fund Management LLC	36,166	$55K	0.0%	-22.6%	0.095%
11/10/2022	Nantahala Capital Management LLC	286,432	$0.44M	0.0%	-7.3%	0.755%
8/15/2022	Nantahala Capital Management LLC	308,978	$0.70M	0.0%	-2.0%	0.815%
8/15/2022	Luminus Management LLC	873,804	$1.98M	0.6%	+15.7%	2.304%
7/22/2022	Geneos Wealth Management Inc.	42,450	$98K	0.0%	-32.0%	0.112%
6/2/2022	Verition Fund Management LLC	36,166	$0.12M	0.0%	N/A	0.095%
5/23/2022	Cantor Fitzgerald L. P.	333,717	$1.12M	0.1%	-20.0%	0.880%
2/15/2022	KCL Capital L.P.	10,000	$54K	0.0%	N/A	0.027%
2/15/2022	Covalis Capital LLP	134,532	$0.72M	0.3%	N/A	0.365%
2/2/2022	New York State Common Retirement Fund	13,800	$74K	0.0%	N/A	0.037%
2/1/2022	Kornitzer Capital Management Inc. KS	133,000	$0.71M	0.0%	N/A	0.361%

Data available starting January 2016

Lucid Diagnostics Inc., a commercial-stage medical diagnostics technology company, focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma in the United States. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Today's Range

Now: $0.67

$0.63

$0.68

50 Day Range

MA: $1.05

$0.67

$1.36

52 Week Range

Now: $0.67

$0.63

$1.85

Volume

235,339 shs

Average Volume

144,898 shs

Market Capitalization

$32.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63

Who are the company insiders with the largest holdings of Lucid Diagnostics?: Lucid Diagnostics' top insider shareholders include:
Stanley Lapidus (Director)
Learn More about top insider investors at Lucid Diagnostics.